Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277679 | 1.00 | TOP2A (0.74) | TOP2AALDH1A1TSHRALOX15FDPS | |
| SCHEMBL28164027 | 1.00 | TOP2A (0.74) | TOP2AALDH1A1TSHRALOX15FDPS | |
| SCHEMBL891291 | 1.00 | TOP2A (0.74) | TOP2AALDH1A1TSHRALOX15FDPS | |
| SCHEMBL891656 | 1.00 | TOP2A (0.74) | TOP2AALDH1A1TSHRALOX15FDPS | |
| SCHEMBL891408 | 0.99 | TOP2A (0.72) | TOP2AALDH1A1TSHRALOX15FDPS | |
| Arachidic Acid SCHEMBL27510532 | 0.95 | TOP2A (0.68) | TOP2AALDH1A1TSHRALOX15FDPS | |
| SCHEMBL891219 | 0.95 | TOP2A (0.66) | TOP2AALDH1A1TSHRFDPSKDM4E | |
| SCHEMBL27603749 | 0.95 | TOP2A (0.65) | TOP2AALDH1A1TSHRFDPSKDM4E | |
| SCHEMBL891275 | 0.94 | TOP2A (0.67) | TOP2AALDH1A1TSHRALOX15RET | |
| SCHEMBL9225446 | 0.93 | TOP2A (0.64) | TOP2AALDH1A1ALOX15KDM4ERET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | claimed |
| EP-2621462-B1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | PROCTER & GAMBLE (US) | 2020-02-12 | — | — | EP | disclosed |
| US-9937115-B2 | Oral care compositions with improved flavor | THE PROCTER & GAMBLE COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| CN-103140209-B | Oral care composition with improved local flavor | 宝洁公司 | 2017-10-13 | — | — | CN | disclosed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | TRPA1, TAS2R40, TAS2R30 | TOP2A 3035/4885ALDH1A1 1558/4885TSHR 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.